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OBJECTIVES: To estimate the cost-effectiveness of using long-acting insulin analogues 
(LAIAs) compared to neutral protamine hagedorn (insulin NPH), in the treatment of 
diabetes mellitus (DM). This information may assist policy makers in making informed 
decisions on reimbursement of LAIAs. METHODS: An economic evaluation, from 
the perspective of a third-party provincial payer, was conducted using the Center
for Outcomes Research (CORE) Diabetes Model (CDM). Clinical outcomes (e.g., 
A1c and hypoglycaemia) were derived from recent meta-analyses. Costs and utilities,
both discounted at 5%, were obtained from published sources. Sensitivity analyses 
were performed to test the robustness of results. RESULTS: Type-1 DM (T1DM) – 
the incremental cost-utility ratio (ICUR) for insulin glargine relative to insulin NPH, 
was $87,932 per Quality Adjusted Life Year (QALY) gained (difference ($) in cost,
$3423; $QALYs, 0.039). The ICUR for insulin detemir relative to insulin NPH, was
$387,729 per QALY gained ($cost, $4,344; $QALYs, 0.011). Type-2 DM (T2DM) – 
the ICUR for insulin glargine relative to insulin NPH, was $642,994 per QALY gained
($cost, $4,945; $QALYs, 0.008). Insulin detemir was more costly ($6,521 per patient) 
and less effective (0.034 QALYs) than insulin NPH. Results were sensitive to 
variations of parameters in sensitivity analyses. CONCLUSIONS: Compared with 
insulin NPH, the use of LAIAs for the treatment of DM was associated with relatively 
high ICURs.
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OBJECTIVES: Diabetes mellitus is an important public health problem in Mexico.
The illness progression is faster when the patient also presents overweight or obesity. 
The objective of this study was to evaluate the clinical and economical impact of the 
use of metformine  sibutramine versus metformine and acarbose as a treatment for 
weight loss in patients with DM-2 with obesity and/or overweight, in Mexico. 
METHODS: Cost-effectiveness analysis by decision tree of the pharmacological treat-
ments for weight loss in patients with diabetes mellitus II from the health service pro-
vider perspective, considering a temporary horizon of 5 years. The considered 
effectiveness measure was the percentage of patients that reaches an IMC a 25 without 
peritoneal dialysis. Costs were estimated using 2008 prices and are expressed in US
dollars (exchange rate of 11.14 pesos/ 1 US dollar). RESULTS: According to the 
model, the effectiveness of each alternative was: metformine, 2.16%; acarbose, 2.16%
and metformine  sibutramine 50.18%. The treatement with metformine threw the 
lowest average cost per treated patient with DM-2 $9,486.3, followed by the treat-
ments with metformine  sibutramine y acarbose with a cost of $10,729.3 y $10,892.0 
respectively. The average treatment cost-effectiveness in ascending order is: met-
formine  sibutramine $21,383.5, metformine $438,183.3; and acarbose $503,116.7. 
The incremental cost of metformine  sibutramine is $2589.1 and acarbose is an 
alternative dominated by metformine. CONCLUSIONS: Metformine  sibutramine is 
a cost-effective alternative from the institutional perspective, in order to accomplish 
the weight loss in patients with diabetes mellitus type 2, with obesity or overweight 
in Mexico.
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OBJECTIVES: The purpose of this study was to compare glucometers used for self-
monitoring blood glucose in diabetic patients available at pharmacy stores by conduct-
ing a cost minimization analysis. METHODS: A prospective cross-sectional study 
design was used. Data was collected from 28 pharmacies, 4 each from local chain
pharmacies namely CVS, Walgreens, Wal-Mart, Kroger, Randall’s (Safeway), Target, 
and HEB in the Houston area. Glucometer use resource cost was calculated from
patient’s perspective and included the price of glucometers, lancet, and strips from
each pharmacy store. The annual effective cost for glucometer use was calculated by
considering number of tests performed by patients per day multiplied by the resource 
cost. A literature search from January 1996 to February 2007 was used to obtain uti-
lization patterns for patients with type 1 and type 2 diabetes (T1D andT2D, respec-
tively). Data was entered in an excel sheet and a cost minimization analysis was
performed. RESULTS: Only 4 generic glucometers were identiﬁ ed in the 28 pharma-
cies, while there were 10 branded glucometers in each. The price of glucometers,
lancets, and strips differed by location and brand. HEB store brand glucometer, In
ControlTM, was the most cost effective generic glucometer (annual cost, T1D $500.9,
T2D $172.2). By selecting the appropriate generic glucometer, patients could save 
annually $125.9 to $148.94 (T1D patients) and $15.25 to $54.4 (T2D patients),
respectively. The most cost effective brand name glucometer was by FreestyleTM 
obtained at Wal-Mart stores (annual cost, T1D $823.7, T2D $307.1). Depending upon 
the appropriately selected brand name glucometer, patients could save annually $168.3 
to $627.6 (T1D patients) and $61.0 to $226.6 (T2D patients), respectively. CONCLU-
SIONS: The cost to use glucometers varied by location and brand selected. Patients
could save cost associated with testing their blood glucose by selecting the right glu-
cometer that ﬁ ts their budget.
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OBJECTIVES: The purpose of this paper is to evaluate the relationship between the 
patient diagnoses and the Claims for total charges for outpatients with diabetes. We
examine treatments in relationship to costs. METHODS: The dataset ‘Outpatient-
base-claim’of size 2,030,078 used for this paper is taken from the Chronic Condition 
Data Warehouse, which contains claim information for the year 2004. In this study, 
we use Summary Statistics, One-Way Frequencies, the Generalized Linear model in
SAS Enterprise Guide 4.1 and Kernel Density Estimation. We utilize Filter and Query,
Append Table, Join Table as well as Random Sampling to preprocess the data in order 
to analyze it. Although this dataset contains ICD9 codes for both diagnosis and pro-
cedures, Deductible and Coinsurance and so on, we mainly concentrate on patient
diagnosis information and total charges. One-way frequency counts gave us the top 
20 reasons for total charges and we use these 20 diagnoses to deﬁ ne 0–1 indicator 
functions for regression. RESULTS: The results of the Summary Statistics show that
the total charges for diagnosis are reduced considerably for payment. Kernel Density 
Estimation shows that the distribution of the total charges follows a Gamma distribu-
tion and most of the charges are under 3500 dollars. The Generalized Linear Model 
shows that only 15 of the newly-generated factors are signiﬁ cant to the model, and
these include Type II diabetes mellitus and chronic kidney disease. Renal failure is the 
most expensive condition to treat. CONCLUSIONS: Diagnosis has an important effect
on the total charges of diabetic patients, but only 15 out of 20 diseases such as
unspeciﬁ ed essential hypertension and chronic kidney disease are statistically signiﬁ -
cant to the total charges. Chronic kidney disease has the most important effect on the
total charges.
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OBJECTIVES: Tennessee residents face a heavy economic burden of diabetes. Costs 
of hospitalization and treatment were $2.9 billion in 2003. This study expands on 
previous work, analyzing race and gender differences in inpatient and outpatient hos-
pital costs for patients with a primary diagnosis of diabetes in Tennessee. We hypoth-
esize that Non-Hispanic Blacks, especially men, bear a disproportionately higher 
burden compared to Non-Hispanic Whites. METHODS: This study utilized inpatient
and outpatient ﬁ les from the 2003 Tennessee Hospital Discharge Data System. Chi-
square and t-tests were performed to analyze signiﬁ cant differences in key demo-
graphic and clinical factors among race-gender groups. Multivariate regression models
were developed to estimate log inpatient and outpatient charges for all hospitalizations 
with a primary diagnosis of diabetes (ICD-9 code: 250). RESULTS: Analyses revealed 
signiﬁ cant differences in comorbid presentations across race-gender groups and other 
factors contributing to charges. Overall, women were signiﬁ cantly more likely to
present with hypertension than men, although percentages for blacks were signiﬁ cantly 
higher (all p  0.001). Ulcers were more prevalent in men versus women (all p  0.001), 
highest among white men (signiﬁ cant only for outpatient events, p  0.001), and 
resulted in signiﬁ cantly higher (48%, p  0.0001) inpatient charges. As predicted, 
hospital charges were highest among blacks, although black males had signiﬁ cantly 
higher (20.2%, p  0.0001) mean inpatient charges and black females had signiﬁ cantly
higher (6.8%, p  0.0001) outpatient charges. CONCLUSIONS: To improve the 
quality of care in diabetes, it is critical to identify disparities in treatment. The analysis
revealed that a signiﬁ cantly higher percentage of men suffered ulcers, which signiﬁ -
cantly increased inpatient charges. As such, gender-targeted education may be war-
ranted to reduce the incidence of diabetic ulcers. In addition, increased prevention 
efforts may be necessary in black communities to reduce avoidable hospitalizations.
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OBJECTIVES: Diabetes is a chronic and potentially disabling disease that represents
an important public health and clinical concern. It is a growing epidemic and the cost 
of treating diabetes is largely increasing. This is ﬁ rst of its kind of research study con-
ducted in Pakistan. This study aimed to estimate the direct cost of Diabetes at out-
patient clinics in Karachi, Pakistan, and to identify the high cost component of diabetes 
care. METHODS: Prevalence based Cost of Illness study was conducted in different 
out-patient clinics representing public, private and NGO/trustee based hospitals of 
Karachi, Pakistan in 2006. After taking informed consent, a pre-tested questionnaire 
was used to collect the data from 345 randomly selected persons with diabetes. 
RESULTS: The only annual mean direct cost tolerated by each person with diabetes 
was estimated to Pakistani rupees 11,580 (US$ 193). We found that increasing age, 
number of complications and longer duration of disease signiﬁ cantly increases the
